BIVI News and Press, BioVie Inc. From 09/12/23

--News Direct-- BioVie chief social impact officer Sarah Hoit joined Steve Darling from Proactive to talk about the growing need for support for individuals suffering from Alzheimer's Disease and their caregivers, including family members. Hoit emphasized that while research into Alzh...

Data from Phase 3 Trial of NE3107 Presented as Poster at the 148 th American Neurological Association Annual Meeting CARSON CITY, Nev., Sept. 11, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage compa...

2023-09-08 09:00:00 ET Summary In 2022, BioVie had reported impressive data from a small Phase 2 trial in Alzheimer’s. In October-November 2023, the company will report topline data from its ongoing Phase 3 trial in Alzheimer's. The reported baseline data of the patient...

CARSON CITY, Nev., Sept. 07, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver diseas...

CARSON CITY, Nev., Aug. 31, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...

New preclinical data characterizing NE3107 mechanism of action featured in oral presentation Phamacokinetic data from Phase 2a study supports potential co-administration of NE3107 with carbidopa/levodopa Separate analysis of Phase 2a study data shows evidence of motor effects of NE3107 in...

2023-08-18 19:19:57 ET Summary BIVI is undervalued if successful in any of its 3 programs [Alzheimer's disease(AD), Parkinson's disease, resistant ascites], but short-term the stock price will depend on upcoming AD phase 3 results. BIVI will soon need to raise cash to support plan...

ORLANDO, FL / ACCESSWIRE / August 11, 2023 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Soligenix, Inc. (Nasdaq:SNGX) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, August 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is avai...

--News Direct-- BioVie Inc CEO Cuong Do joined Steve Darling from Proactive to provide an update to shareholders on the company's progress in developing innovative drug therapies for advanced liver disease, as well as neurological and neurodegenerative disorders. In a letter to shareh...

Treatment with NE3107 led to >50% reductions in DNA methylation of 400 CpGs* and some in a manner that was significantly correlated to observed clinical improvements in cognition and various biomarkers. Over 3,000 significant correlations were found linking reductions in DNA methylati...